New drug combo aims to shield kidneys in type 1 diabetes
NCT ID NCT06072326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining dapagliflozin (a diabetes drug) with SC0062 (a blood vessel drug) can better protect kidneys in adults with type 1 diabetes and chronic kidney disease. Thirty-six participants will try each treatment alone and together in a cross-over design. The main goal is to see if the combo reduces protein in urine, a sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapagliflozin (SGLT2 inhibitor) and SC0062 (endothelin receptor antagonist)
- What this could lead to
- If successful, this combination could offer a new way to protect kidneys in people with type 1 diabetes and slow kidney disease progression.
- What could go wrong
- This is a small, early-phase trial (36 people) testing short-term effects. The drugs may not work as hoped or could cause side effects like fluid retention or ketoacidosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS WITH DIABETIC NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam University Academic Center
Amsterdam, North Holland, 1081 HV, Netherlands
-
Regionshospitalet Gødstrup
Herning, 7400, Denmark
-
Steno Diabetes Center Aarhus
Aarhus, 8200, Denmark
-
Steno Diabetes Center Copenhagen
Copenhagen, 2730 Herlev, Denmark
-
Turku University Hospital
Turku, 20520, Finland
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9700 RB, Netherlands
-
University of Helsinki
Helsinki, Uusimaa, 00029 HUS, Finland